Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.7.1985PMID 11283131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

  1999cited by this paper
• The changing epidemiology of esophageal cancer.

  1999cited by this paper
• Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.

  1999cited by this paper
• Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

  1999cited by this paper
• Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

  1998cited by this paper
• The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.

  1997cited by this paper
• Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods.

  1997cited by this paper
• Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

  1997cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• Adjuvant and neoadjuvant therapy for gastric cancer.

  1996cited by this paper
• Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

  1996cited by this paper
• Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

  1994cited by this paper
• Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.

  1993cited by this paper
• Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

  1992cited by this paper
• An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis

  1988cited by this paper
• Antineoplastic Agents: the Importance of Sequence of Administration'

  year unknowncited by this paper

• Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

  2025cites this paper
• Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms.

  2022cites this paper
• The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer

  2021cites this paper
• Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach

  2021cites this paper
• Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery

  2020cites this paper
• Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma

  2019cites this paper
• Potent Cytotoxic Natural Flavonoids: The Limits of Perspective.

  2019cites this paper
• Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review

  2018cites this paper
• Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

  2018cites this paper
• Molecular Prognostic Factors in Gastric Cancer

  2017cites this paper
• Targeted Therapy in Advanced Gastric Cancer

  2017cites this paper
• African Plants with Antiproliferative Properties

  2017cites this paper
• Inhibitors of cyclin‐dependent kinases as cancer therapeutics

  2017cites this paper
• Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.

  2016cites this paper
• New advances in targeted gastric cancer treatment.

  2016cites this paper
• Molecular targeted therapy for the treatment of gastric cancer

  2016cites this paper
• Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

  2016cites this paper
• Cyclin dependent kinase modulation as a new therapeutic approach

  2016cites this paper
• Flavonoids, Flavonoid Subclasses, and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies

  2016cites this paper
• Uncovering New Roles For The Aryl Hydrocarbon Receptor (AHR) In Breast Cancer

  2016cites this paper
• Emerging kinase inhibitors of the treatment of gastric cancer

  2015cites this paper
• Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA)

  2015cites this paper
• Targeted Therapies for Gastric Cancer

  2015cites this paper
• Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products

  2015cites this paper
• Dietary Intake of Flavonoids, Barrett's Esophagus Development, and Esophageal and Gastric Cancer Incidence and Survival

  2014cites this paper
• Promise of Cyclin-Dependent Kinases 4/6 as Therapeutic Targets in Breast Cancer

  2014cites this paper
• Breast Cancer Foundation ( to L . L . ) Supported in part by grantsPathways to Induce Apoptosis 1 Antiapoptotic Functions of Bcl-2 and Target Protein Kinase C Novel Extranuclear-targeted Anthracyclines Override the Updated

  2014cites this paper
• Clinical Study A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma

  2014cites this paper
• Recent advances and future trends in the targeted therapy of metastatic gastric cancer

  2014cites this paper
• Target driven preclinical screening for new antimitotic chemotherapy agents.

  2014cites this paper
• Targeted therapy in advanced gastric carcinoma: the future is beginning.

  2014cites this paper
• Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.

  2014cites this paper
• Risikofaktoren für das Adenokarzinom des Ösophagus

  2014cites this paper
• Emerging drug profile: cyclin-dependent kinase inhibitors

  2013cites this paper
• Targeting the Cell Cycle for Cancer Treatment and Neuroprotection

  2013cites this paper
• high-risk chronic lymphocytic leukemia associated with marked clinical efficacy in refractory, genetically Flavopiridol administered using a pharmacologically derived schedule is

  2013cites this paper
• A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

  2013cites this paper
• A novel approach to the design of selective inhibitors for cell cycle cyclin dependent kinases

  2013cites this paper
• First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

  2012cites this paper
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies

  2012cites this paper
• A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors

  2012cites this paper
• Targeted therapy for gastric adenocarcinoma.

  2012cites this paper
• Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.

  2012cites this paper
• Slow-Cycling Cancer Cells: A Dissertation

  2012cites this paper
• Cyclin dependent kinases in cancer

  2012cites this paper
• Discovery of new anticancer agents from higher plants.

  2012cites this paper
• Translational Oncogenomics and Human Cancer Interactome Networks: Recent Developments, Complex System Dynamic Approaches and Novel Techniques

  2012cites this paper
• Phase I and II clinical trials for gastric cancer.

  2012cites this paper
• Clinical Pharmacokinetics of Flavonoids

  2012cites this paper
• Clinical Trials in Cancer and Pharmacogenomics: A Critical Evaluation

  2012cites this paper
• Cyclin dependent protein kinases as drug targets - potential in cardiovascular diseases

  2011cites this paper
• Targeted Therapeutics in Cancer Treatment

  2011cites this paper
• Translational Oncogenomics and Human Cancer Interactome Networks : Techniques and Complex System Dynamic Approaches

  2011cites this paper
• Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.

  2011cites this paper
• The Analysis of Bionetwork Dynamics 2. Techniques and Application Examples 2.1. DNA Microarrays 2.2. Oligonucleotide Arrays 2.3. Gene Expression – Microarray Data Analysis 2.4. Protein Microarrays 2.5. Tissue Arrays 2.6. Fluorescence Correlation Spectroscopy and Fluorescence Cross--Correlation Spect

  2011cites this paper
• Incorporation of targeted agents in the management of patients with advanced gastric cancer.

  2011cites this paper
• Targeted Therapies for Gastric Cancer

  2011cites this paper
• Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging

  2011cites this paper
• The CDK inhibitors in cancer research and therapy

  2011cites this paper
• Pharmacokinetic-Pharmacodynamic and Pharmacogenetic Studies of Flavopiridol and its Glucuronide Metabolite

  2011cites this paper
• A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model.

  2010cites this paper
• Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.

  2010cites this paper
• Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.

  2010cites this paper
• A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer

  2010cites this paper
• Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München

  2010cites this paper
• Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

  2010cites this paper
• Novel mechanisms of flavopiridol

  2010cites this paper
• Cyclin‐dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T‐cell leukemia Jurkat cells

  2010cites this paper
• Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes.

  2009cites this paper
• Flavopiridol (alvocidib) in chronic lymphocytic leukemia

  2009cites this paper
• Gastric cancer in the era of molecularly targeted agents: current drug development strategies

  2009cites this paper
• Flavopiridol in chronic lymphocytic leukemia: a concise review.

  2009cites this paper
• Systemic treatment of gastric cancer.

  2009cites this paper
• Targeting the Cell Cycle to Kill Cancer Cells

  2009cites this paper
• Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage

  2009cites this paper
• A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism*

  2009cites this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cites this paper
• Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

  2009cites this paper
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  2009cites this paper
• Strategies for surviving down-regulation : effects on tumour cell growth potential and chemosensitivity profile

  2008cites this paper
• New Therapies in Chronic Lymphocytic Leukemia

  2008cites this paper
• Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.

  2008cites this paper
• CDK Inhibitors as Anticancer Agents

  2008cites this paper
• Flavopiridol displays preclinical activity in acute lymphoblastic leukemia

  2008cites this paper
• Chapter 22 CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Molecular Targeting in Upper Gastrointestinal Malignancies

  2008cites this paper
• Control of the Cell Cycle

  2008cites this paper
• Cyclin-dependent kinases as tumor initiators and therapeutic targets

  2008cites this paper
• New combination therapies with cell-cycle agents.

  2008cites this paper
• CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials.

  2008cites this paper
• The Cell Cycle

  2008cites this paper
• The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

  2008cites this paper
• Targeted therapy for oesophageal cancer: an overview

  2008cites this paper
• Enhancing the cytotoxic activity of novel targeted therapies--is there a role for a combinatorial approach?

  2008cites this paper
• Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics

  2008cites this paper
• Modulation of the functional binding sites for TGF-β on the type II receptor leads to suppression of TGF-β signaling

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

  2007cites this paper
• Flavopiridol in the treatment of chronic lymphocytic leukemia

  2007cites this paper
• Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling.

  2007cites this paper